DermLine
Newsletter of the American Osteopathic College of Dermatology

March 29 - April 1 | Atlanta, GA
Introducing the 2017 Spring Meeting Faculty

Karthik Krishnamurthy, DO, FAOCD

Program Chair
Dr. Krishnamurthy is a board-certified dermatologist and a member of the American Academy of Dermatology and was elected to serve as the National President of the American Osteopathic College of Dermatology in 2016. Dr. Krishnamurthy graduated from the University of Missouri with dual degrees in Biochemistry and Medicinal Chemistry and received his medical degree from Nova Southeastern University. After his internship at Cook County Hospital in Chicago, IL, Dr. Krishnamurthy completed his dermatology training at St. Barnabas Hospital in New York, NY, where he served as chief resident.

Dr. Krishnamurthy then joined the academic faculty as Associate Professor at the Albert Einstein College of Medicine in New York, where he served as Chief of Dermatology for Jacobi Medical Center, the largest public hospital in New York City and created a cosmetic and laser dermatology program at Montefiore Medical Center, serving as its director. Devoted to education, he trained residents daily, and was awarded “Teacher of the Year” in 2014. Dr. Krishnamurthy’s commitment to leadership and research has been recognized by the Kenneth Burnell Research Scholarship, Intedris Research Award, Allergan Research Grant, New York Academy of Medicine and American Academy of Dermatology. Paralleling his academic pursuits, Dr. Krishnamurthy was the recipient of the 2011 Academic Dermatology Leadership Program and the 2012 Editorial Mentorship program, both granted by the American Academy of Dermatology. In addition, he serves as Editor-in-Chief of the Journal of the American Osteopathic College of Dermatology, has published in prestigious journals and texts, including the Journal of Investigative Dermatology, the Journal of the American Academy of Dermatology and Dermatologic Surgery and co-authored the textbook Emergencies in Dermatology.

Given his exposure to the varied culture, ethnicity, skin-types and demographics in New York City, Dr. Krishnamurthy is an expert in complex medical dermatology, especially psoriasis, vitiligo, auto-immune diseases (lupus) and phototherapy/excimer laser, as well as dermatologic surgery, nail surgery, earlobe repair and cosmetic/injectable/laser dermatology. He is often called upon as a media expert, contributing to the New York Times, the L.A. Times, Washington Post, WebMD, CBS News, Yahoo News, Good Housekeeping and Weather.com. He relocated to Greater Jacksonville, FL with his wife, Dr. Aneesa Krishnamurthy (Rheumatologist) and twin sons.

Jeff Benabio, MD
Managing Your Online Reputation
This lecture will be an overview of various social and reputational online platforms, explanation of why they are important and teaching best practices to manage them.

Objectives:
1. Help attendees assess their current online reputation
2. Help attendees differentiate between different social and reputational platforms
3. Review how to actively manage your reputation, including addressing bad reviews

Needs:
1. Legislative, regulatory, or organizational changes effecting patient care

References:
1. Why Physicians are Embracing Online Patient Reviews. Physicians Practice. 6 Jan 16.

Core Competencies: 4, 5
Dr. Benabio grew up in a small Italian neighborhood in Rhode Island, where he developed a life-long love for the Red Sox, pasta and Dunkin Donuts. He earned a BA from Providence College and an MA from Brown University. After working in alcohol and addiction studies at Brown, he and his wife moved to North Carolina where he was project manager of a stroke study at UNC-Chapel Hill. In 2003, he graduated first in his class from Wake Forest University School of Medicine, where he also served as Class President, President of Alpha Omega Alpha and was the recipient of the prestigious Faculty Award. He completed his medical internship at Scripps Mercy Hospital in San Diego and his dermatology residency at UC Irvine, where he was named chief resident.

Currently, Dr. Benabio is Physician Director of Healthcare Transformation, at Kaiser Permanente in San Diego, CA. In addition to being a board-certified practicing dermatologist, he leads one of the country’s largest telehealth programs and is also a leading voice for using social technologies to benefit healthcare teams and to empower patients. He is a member of the Re-imaging Ambulatory Design (RAD), Health Information Process Transformation (HIPT) and Telehealth committee at Kaiser Permanente. He serves on several boards, including the External Advisory Board for the Mayo Clinic Center for Social Media and writes “Digital Doctor,” a monthly column about digital medicine published in Skin & Allergy News, Pediatric News, Hospitalist News, Rheumatology News, GI and Hepatology News and Family Practice News. He has been quoted in numerous publications including the Wall Street Journal, USA Today, CNN and O, The Oprah Magazine. Perhaps, most importantly, Glamour magazine named him “A Rock Star of Dermatology.”

Over the last five years, Dr. Benabio has given over 50 lectures and keynote addresses on topics including social networking, reputation management, patient empowerment, health information technology, healthcare design and telehealth. When he isn’t practicing medicine or blogging, he can found on a Southwest Airlines flight most likely reading a biography of Teddy Roosevelt or Winston Churchill on his kindle.

Disclosures: No disclosures provided by speaker

Larissa Chismar, MD

Challenges in Dermatopathology

This lecture will discuss the importance of detailed communication between the dermatologist and dermatopathologist. We will then discuss challenging cases that require correlation with the clinical and histologic findings, focusing on examples of difficult melanocytic lesions, soft tissue tumors and inflammatory conditions.

Objectives:
1. Review what information is important to include on dermatopathology requisition forms and why dermatopathologists may encounter diagnostic difficulty without this information
2. Review challenges encountered by dermatopathologists in the interpretation of melanocytic neoplasms, soft tissue neoplasms and inflammatory conditions
3. Review diagnostic pitfalls that may arise with partial biopsies

Needs:
1. New methods of diagnosis or treatment
2. Advances in medical knowledge

References:

Core Competencies: 2, 3, 4, 5, 6

Dr. Larissa Chismar is a board-certified dermatologist and dermatopathologist.

Dr. Chismar earned her medical degree from Albert Einstein College of Medicine in Bronx, NY. She completed her residency training in dermatology and fellowship training in dermatology at Montefiore Medical Center in Bronx, NY.

Dr. Chismar is a member of American Society of Dermatopathology, American Academy of Dermatology, International Society of Dermatopathology, Alpha Omega Alpha Honor Medical Society, Atlanta Association of Dermatology and Dermatologic Surgery and American Medical Association.

Disclosures: No disclosures provided by speaker

Lloyd Cleaver, DO, FAOCD

Osteopathic Continuous Certification Update

Objectives:
1. Review the OCC process that ensures osteopathic physicians are current in their specialty

Karthik Krishnamurthy, DO, FAOCD
Now Approved!

Learn more at our booth

Visit www.EucrisaHCP.com for more information
2. Review the five components of OCC which include, Unrestricted License, Lifelong Learning, Cognitive Assessment, Practice Performance and Continuous AOA Membership

Needs:
1. Ensuring college membership understands new requirements for accreditation and maintenance of our board certification

References:

Core Competencies: 1, 3, 5, 6

Dr. Lloyd Cleaver, DO founded the Cleaver Dermatology Clinic in 1986. Dr. Cleaver completed his internship and residency at the Navy Regional Medical Center in San Diego, CA. He is a graduate of Kirksville College of Osteopathic Medicine. He is also a board-certified dermatologist, Fellow of American Osteopathic College of Dermatology and board-certified in Mohs micrographic surgery.

A leader in medical education, Dr. Cleaver is a Professor of Dermatology at the Kirksville College of Osteopathic Medicine/A.T. Still University and Assistant Dean of Continuing Medical Education at the Kirksville Osteopathic Medical Center/A.T. Still University. He serves as Vice Chair for the Certification Committee of American Osteopathic Association and has been Vice Chair and is currently Secretary to the American Osteopathic Board of Dermatology. He is a Past President of the Kirksville Osteopathic Alumni Association and a Past President of American Osteopathic College of Dermatology.

Disclosures: No disclosures provided by speaker

Eugene Conte, DO, FAOCD
Osteopathic Dermatology Research and the Foundation for Osteopathic Dermatology

This lecture will discuss the current ongoing osteopathic dermatology research projects being funded by the FOD and discuss in detail the grants available to an osteopathic dermatologist and abstract presentations.

Objectives:
1. Discuss how the Foundation for Osteopathic Dermatology (FOD) supports osteopathic dermatology research
2. Discuss the multiple grants available to an osteopathic dermatologist who wants to pursue research
3. Present “abstracts” from ongoing research projects

Needs:
1. New advances in dermatologic treatment
2. New methods of diagnosis or treatment
3. Development of new technology
4. Advances in medical knowledge

References: Pending

Core Competencies: 1, 2, 3

Dr. Eugene Conte earned his medical degree from Michigan State University College of Osteopathic Medicine. He completed his dermatology internship and residency at Pontiac Osteopathic Hospital.

Dr. Conte serves as Assistant Clinical Professor of Dermatology at Michigan State University, Ohio University College of Osteopathic Medicine and Wright State University. At Grandview Medical Center, he is Chairman of the Department of Dermatology.

Dr. Conte is a diplomate of the American Osteopathic Board of Dermatology and the National Osteopathic Board of Medical Examiners. With more than 25 years of experience, he is a Fellow of the American Osteopathic College of Dermatology and has served as President of this prestigious organization.

Disclosures: Speaker for Lilly, Janssen Biotech, Abbvie, Celgene

John Coppola, DO, FAOCD
20 Tricks to Finishing Your Office Day On Time

This lecture offers a myriad of tips on running your medical and surgical dermatology practice patient schedule on time to improve patient satisfaction and reduce physician burn out.

Objectives:
1. Review how to incorporate health-based technology into your practice
2. Review how to improve office and patient flow to improve efficiency

Needs:
1. Development of new technology
2. Legislative, regulatory, or organizational changes effecting patient care

References: Pending

Core Competencies: 3, 4, 5

John C. Coppola, DO, is a board-certified dermatologist and skin cancer surgeon with advanced training in a wide array of skin conditions and cosmetic procedures. A Clearwater Floridian, Dr. Coppola earned his Bachelor of Science degree from the University of North Carolina at Chapel Hill. After receiving his medical degree with
highest honors from Nova Southeastern University, he completed his dermatology residency at Michigan State University Botsford Hospital and served as chief resident his final year.

Dr. Coppola currently enjoys training the next generation of physicians as a clinical associate professor for Florida State University’s College of Medicine. His previous teaching appointments included serving as a clinical instructor of Michigan State University while in private practice in Michigan. He is the author of numerous published journal articles and is now active in dermatologic medical research.

His passion for personalized care focuses on three key tenets: preventing sun damage, educating his patients on skin health & vitality and getting to know his patients also as people (for military veterans, he is eternally grateful for their service). When not at work, he can be found most days spending time playing with his German shepherd “Grizzly”.

Disclosures: No disclosures provided by speaker

Salma Faghri de la Feld, MD
Clues in Contact Dermatitis
This lecture will provide an overview of patch testing process and clinical clues to eyelid, lip and facial allergic contact dermatitis including common allergens and avoidance tips. Overview of systemic contact dermatitis with focus on nickel and balsam of Peru.

Objectives:
1. Provide attendees with an overview of patch testing and whether patients can be patch tested while on immunosuppressants
2. Help attendees recognize clues to determining the causes of localized contact dermatitis (specifically eyelid, lip and facial dermatitis)
3. Review causes of systemic contact dermatitis, including nickel and balsam of Peru

Needs:
1. Advances in medical knowledge

References:

Core Competencies: 2

Dr. Salma Faghri de la Feld is a board-certified dermatologist.

Dr. Faghri de la Feld earned her medical degree from the Warren Albert School of Medicine at Brown University in Providence, RI.
She completed her internship at Brown University/Rhode Island Hospital in Providence, RI. Dr. Faghri de la Feld completed her dermatology residency at University of Alabama School of Medicine in Birmingham, AL, where she served as chief resident. She is an Assistant Professor of Dermatology at Emory University.

Disclosures: No disclosures provided by speaker

Ron Feldman, MD

Bullous Disease as a Window Into the Body
This lecture will provide mechanisms of autoimmune bullous diseases with a unique perspective on how these diseases can provide insight into other systemic processes.

Objectives:
1. Define mechanisms of autoimmune bullous diseases
2. Help attendees understand how bullous diseases can provide insight into systemic disease
3. Review treatments for both bullous diseases and related systemic diseases

Needs:
1. New methods of diagnosis or treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge

References:

Core Competencies: 2, 3

Dr. Ron Feldman is a board-certified dermatologist.

Dr. Feldman received a Bachelor of Science degree from College of Charleston in Charleston, SC. He earned his medical degree and a Ph.D from the Medical University of South Carolina in Charleston, SC. Dr. Feldman completed his dermatology residency at Cleveland Clinic in Cleveland, OH and an autoimmune blistering disease fellowship at the Center for Blistering Diseases in Boston, MA.

Disclosures: Consultant for Eli Lilly

Michelle Foley, DO, FAOCD

A Decade of Lessons Learned the Hard Way: Practical Knowledge for the Medical and Cosmetic Dermatologist and Practice Owner
This lecture will present and discuss the failure and success of treatment of difficult medical and cosmetic cases, as well as the failure and success of decisions facing the practice owner.

Objectives:
1. Present alternative therapies to treat difficult cases that previously failed common treatment or are easily misdiagnosed
2. Present a streamlined approach to cosmetic patients in your office that will increase both your profit margin and patient satisfaction
3. Present both tried, failed and successful strategies for growth of your medical and cosmetic practice

Needs:
1. New methods of diagnosis and treatment
2. Advances in medical knowledge

References:

Core Competencies: 1, 2, 3, 6

Dr. Michelle Foley is a board-certified dermatologist specializing in medical and surgical dermatology, with a passion for nonsurgical aesthetics and facial rejuvenation. Her practice approach is to provide personalized care and education for each of her patients. Dr. Foley works with both men and women to help them look their best utilizing noninvasive techniques; combining injectables, topical agents, lasers and physician-strength skin care. “Best results are always achieved when you partner with your patient to build a treatment plan that is right for that individual. Cosmetic dermatology is not a one-size-fits-all world,” she explains.

Dr. Foley was born in Alabama and grew up on the west coast of Florida. After graduating Summa Cum Laude from Florida State University, she attended Nova Southeastern University College of Osteopathic Medicine in Ft. Lauderdale, FL. There she graduated with the highest of honors and received the Terry Internal Medicine Award for the highest achievement in academic and clinical internal medicine. Dr. Foley completed her dermatology training at Michigan State University/POH.
Regional Medical center in Detroit, Michigan where she served as the chief resident.

Locally, Dr. Foley is an Associate Clinical Professor for Florida State University College of Medicine and a volunteer educator for Halifax Hospital Family Medicine Program. She also serves as the Associate Editor for the Journal of the American Osteopathic College of Dermatology.

Disclosures: No disclosures provided by speaker

Adam Friedman, MD

Urticaria: Diagnosis and Treatment Considerations

This lecture will highlight the common condition many do not appropriately know how to manage.

Objective:
1. Review how to recognize urticaria and formulate appropriate workups

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge

References:
2. The Diagnosis and Management of Acute and Chronic Urticaria, 2014 Update, JACI. 2014;133(3):1270-77.

Core Competencies: 1, 2, 3, 6

Adam Friedman, MD, FAAD, is an Associate Professor of Dermatology and serves as Residency Program Director and Director of Translational Research in the Department of Dermatology at the George Washington University School of Medicine and Health Sciences.

Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York. He completed his internship at New York Hospital Queens and returned to Einstein for his dermatology residency and was appointed chief resident during his final year.

Dr. Friedman joined the Einstein faculty after graduation from 2010-2015, during which time he was the Director of Dermatologic Research, Director of the Translational Research Fellowship and the Associate Program Director. Dr. Friedman is currently investigating novel nanotechnologies that allow for controlled and sustained delivery of a wide spectrum of physiologically and medicinally relevant molecules, with an emphasis on treating infectious diseases, accelerating wound healing, immune modulation and correcting vascular dysfunction. In line with his research interests, he serves as Vice President of the Nanodermatology Society. Dr. Friedman was recently appointed as President of the Dermatology Section of the New York Academy of Medicine.

Dr. Friedman is also committed to resident and medical education. He chaired the leadership workgroup of the American Academy of Dermatology Resident/Fellows Committee, currently serves on the Sulzberger Committee on Education and is the Senior Editor of the Dermatology In-Review Online Workshop. Dr. Friedman serves as the Dermatology Expert for healthguru.com and publishes a column on Everyday Health entitled “The Skin You’re In.”

Disclosures: Speaker for Janssen Biotech, Inc.; Consultant for Galderma, Encore, Pfizer

Melinda Greenfield, DO, FAOCD

Fermentation, Civilization and the Microbiome

This lecture will review the history of fermentation and how it has contributed to the health of human civilization, introduce the human microbiome and emphasize the importance of understanding a healthy microbiome as a practicing dermatologist.

Objectives:
1. Review the process of fermentation and how it has contributed to the history and health of human civilization
2. Review the human microbiome and the importance of maintaining a healthy microbial ecosystem
3. Relate the healthy microbiome to the practice of dermatology

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge

References:

Core Competencies: 2, 3

Melinda F. Greenfield is a board-certified dermatologist specializing in the diagnosis and treatment of the skin, hair and nails. Her additional areas of expertise include cutaneous surgery, Botox, fillers, leg vein treatment (sclerotherapy) and other cosmetic procedures.

Dr. Greenfield has been in Albany, GA since 2000 and has quickly become a local and regional expert in the field of dermatology. She is on the speaker’s board for several pharmaceutical companies and lectures for many local and regional groups. She especially enjoys educating the community on the dangers of the sun and skin cancer.
She is an Associate Clinical Professor at the Georgia Campus of the Philadelphia College of Osteopathic Medicine and the Georgia Health Sciences University (Medical College of Georgia). She is on the board of the Dougherty County Medical Society, as well as the Georgia Osteopathic Medical Association. She served as president of the Georgia Osteopathic Medical Association for the 2011-2012 term. She is also an Associate Editor of the *Journal of the American Osteopathic College of Dermatology*.

Dr. Greenfield received her Bachelor of Science degree from the University of Maryland and received her medical degree with honors from Nova Southeastern University in Ft. Lauderdale, FL. She completed a year of internal medicine at Sinai Hospital of Baltimore prior to her three year dermatology residency at St. Barnabas Hospital in Bronx, NY.

She lives in Albany, GA with her husband, Carl and two children, Nathan and Josie. In her spare time she enjoys cooking, reading, tending to her 8 cats and 1 dog and training for various running races and triathlons.

*Disclosures: No disclosures provided by speaker*

**Charles Gropper, MD**

**HIV In Dermatology**

This lecture will be a review of epidemiology, clinical features and management strategies for a variety of infectious, inflammatory and neoplastic skin conditions associated with HIV. Special emphasis will be placed on the need to be aware that a variety of common and rare skin conditions can be markers of HIV infection.

**Objectives:**
1. Review epidemiology of HIV as pertains to dermatology
2. Review cutaneous manifestations of HIV infection
3. Review treatment options for various HIV-related skin conditions

**Needs:**
1. Advances in medical knowledge

**References:**

**Core Competencies:** 2, 3

Charles A. Gropper, MD, is a board-certified dermatologist who is a diplomate of the American Board of Dermatology and the National Board of Medical Examiners. Currently, Dr. Gropper is an Associate Clinical Professor of Dermatology at the Mount Sinai School of Medicine, as well as a dermatopharmacology peer reviewer for the *Lancet Journal*.

Dr. Gropper graduated with an Artium Baccalaureatus (A.B.) degree with magna cum laude honors from Brown University in Providence, RI. He attended the University of Pennsylvania School of Medicine where he received his medical degree. After completing his education, Dr. Gropper completed an internal medicine internship at the Mount Sinai Hospital followed by a residency in dermatology at Albert Einstein College of Medicine and a fellowship in dermatopharmacology at New York University Medical Center.

For over 18 years, Dr. Gropper has practiced medicine in hospitals and private practices in New York, Brooklyn and the Bronx. He has also held positions as Chief of Dermatology and Associate Clinical Professor of Dermatology. Currently, he is Chief of Dermatology at St. Barnabas Hospital in the Bronx. He has co-authored numerous professional articles and book chapters related to dermatology and dermatopharmacology. He has received over a dozen awards for significant contributions, teacher of the year, educating residents and exceptional service.

*Disclosures: No disclosures provided by speaker*

**Cindy Hoffman, DO, FAOCD**

**Great Cases From Osteopathic Institutions**

**Objectives:**
1. Present interesting cases
2. Discuss treatment of the interesting cases

**Needs:**
1. New advances in dermatologic treatment
2. New methods of diagnosis or treatment
3. Development of new technology
4. Advances in medical knowledge

**References:** Pending

**Core Competencies:** 2, 3, 4, 5, 6

*Disclosures: No disclosures provided by speaker*
For eczema-prone skin

TWO ADVANCED TECHNOLOGIES.

HYDRATE

ONE REPLENISHING REGIMEN.

Cetaphil® RestoraDerm® products are the first and only regimen with advanced ceramide and Filaggrin technology™

To help restore the skin barrier in dry, eczema-prone skin, recommend the Cetaphil® RestoraDerm® regimen.¹

Beth McLellan, MD

**Cases In Oncodermatology**

This lecture will review some common reactions to cancer therapies, as well as dermatologic problems in cancer survivors in case-based approach. Reactions covered will include: hand foot skin reactions, papulopustular eruption, onycholysis, cutaneous metastases, nummular dermatitis of the reconstructed breast and secondary skin cancers following radiation therapy.

**Objectives:**

1. Review how to recognize and manage common side effects from traditional and targeted chemotherapeutic agents, including hand foot skin reaction, papulopustular eruption and onycholysis
2. Help attendees improve communication with on oncologists by using common terminology and grading systems for treatment-related toxicities
3. Review the importance of dermatologic care in cancer survivors, especially surveillance for secondary skin cancers

**Needs:**

1. Advances in medical knowledge

**References:**


**Core Competencies:** 2, 3, 4, 7

Beth McLellan, MD is a board-certified dermatologist and researcher in Montefiore’s Division of Dermatology and with Montefiore Einstein Center for Cancer Care. She is also Director of Dermatology at Jacobi Medical Center. She is committed to improving oncology patients’ quality of life and preventing interruptions in their care.

Prior to joining Montefiore, Dr. McLellan served as a full-time faculty member at New York University where she saw all inpatient dermatology consults and developed an oncodermatology program. Her medical training includes an internship in internal medicine at Loyola Medicine and dermatology residency at Henry Ford Health System in Detroit, where she served as chief resident and initiated a supportive oncodermatology clinic. Dr. McLellan received additional oncodermatology training at Memorial Sloan Kettering Cancer Center and at the Institute Gustave Roussy in Paris. She has received awards from the Women’s Dermatology Society and the Dermatology Foundation. She regularly lectures at both dermatology and oncology meetings and is actively involved in teaching medical students and residents.

Dr. McLellan specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies. Dr. McLellan has received a Career Development Award from the Dermatology Foundation to study hair loss in breast cancer patients on hormonal treatments. In addition to hair loss, her research interests include hand foot syndrome and radiation dermatitis.

Dr. McLellan has published numerous articles and textbook chapters related to supportive oncodermatology. She is regularly invited to speak at dermatology and oncology conferences including, the annual meeting of the American Academy of Dermatology, the South Beach Symposium and the International Symposium for Supportive Care in Cancer.

**Disclosures:** Stockholder of Spruce Health; Advisor for Spruce Health; Consultant for Biopelle

**AAD Billing and Coding Update**

Learn how to easily identify appropriate dermatology codes and correct use/application of such codes for services/procedures performed in your practice to ensure accurate claim submission, as well as proper code identification and application for more complex procedures to accurately reflect the services provided.

**Objectives:**

1. Review what’s new and revised in coding and regulatory updates pertaining to dermatology in 2017
2. Review the appropriate coding guidelines and concepts using easy to understand methodologies of code selection and application
3. Review how to easily identify appropriate dermatology codes and the correct use/application of such codes for services procedures performed in your practice to ensure accurate claim submission as well as proper code identification

**Needs:**

1. Legislative, regulatory, or organizational changes effecting patient care
Carlos Nousari, MD  
**Photosensitive Disorders in Middle Age and Beyond**  
This lecture will explore the various photodermatoses potentially encountered in clinical practice. An emphasis will be placed on clinical diagnosis tips, how to interpret antibody results and the pathophysiology of the different disease processes.

**Objectives:**  
1. Discuss the clinical presentations and histological features of various photodermatoses  
2. Explore the pathophysiology of ultraviolet-mediated diseases  
3. Understand how to interpret the antibodies tested in various photodermatoses

**Needs:**  
1. New advances in dermatologic treatment  
2. New methods of diagnosis or treatment  
3. Advances in medical knowledge

**References:**  

**Core Competencies:** 2, 3

Carlos Nousari, MD is nationally and internationally recognized as a leading authority in dermatoiimmunology. He is a clinician, a researcher and a prolific author in the areas of dermatoimmunology, dermatopathology and immunofluorescence. In particular, he has conducted extensive research in autoimmune blistering diseases, connective tissue disorders and vasculitides.

Prior to joining Dermpath Diagnostics in June 2004, Dr. Nousari served as co-director of the Division of Immunodermatology at Johns Hopkins Medical Institute in Baltimore, MD and as chairman of the Department of Dermatology and Director of Dermatopathology and Immunodermatology at the Cleveland Clinic Florida in Weston. Dr. Nousari is currently the program director of the Broward Health Medical Center Dermatology Residency Program. He also serves as the Medical Director at Dermpath Diagnostics South Florida and the Director of the Institute for Immunofluorescence. Dr. Nousari is a Professor of Dermatology at the University of Miami, University of Florida and Nova Southeastern University where he runs an immunobullous clinic.

Disclosures: No disclosures provided by speaker

Leslie Potter Lawley, MD  
**Look-Alikes, Controversies and What’s New in Pediatric Dermatology**  
This lecture will compare and contrast several pediatric dermatology diagnoses, including vascular birthmarks (specifically infantile...
hemangiomas and capillary malformations), forms of infected atopic dermatitis, and infantile cutaneous tumors (specifically nevus sebaceous, mastocytoma, and juvenile xanthogranuloma) and highlight recent literature applicable to these topics.

Objectives:
1. Distinguish clinical features of infantile hemangiomas and capillary vascular malformations (i.e. port wine stains) and understand systemic implications of each
2. Differentiate clinical features of secondary infections complicating atopic dermatitis including eczema, herpeticum, eczema coxsackium and impetiginized eczema
3. Review the current literature regarding the risks of tumor development within nevus sebaceous birthmarks

Needs:
1. New advances in dermatologic treatment
2. New methods of diagnosis or treatment
3. Availability of new medication(s) or indication(s)
4. Advances in medical knowledge

References:

Core Competencies: 2, 3

Dr. Leslie Potter Lawley is a board-certified dermatologist and pediatric dermatologist.

Dr. Lawley earned her medical degree from Emory University School of Medicine in Atlanta, GA. She completed an internship and her dermatology residency training at Emory University Hospital in Atlanta, GA. She then completed a fellowship in pediatric dermatology at Northwestern University Medical School in Chicago, IL.

Dr. Lawley is a member of the American Academy of Dermatology, American Medical Association, Society of Investigative Dermatology, Society of Pediatric Dermatology, Women’s Dermatologic Association.

Disclosures: Content author for Up To Date

Zakiya Rice, MD

Don’t Sweat It: Treatments for Hyperhidrosis
This lecture will discuss the large portion of patients that suffer from hyperhidrosis. There is an undeniable need for more practitioners that know how to diagnose and treat hyperhidrosis.

Objectives:
1. Review quality of life impact of hyperhidrosis
2. Review known pathogenesis of hyperhidrosis
3. Review treatment of hyperhidrosis

Needs:
1. New advances in dermatologic treatment
2. New methods of diagnosis or treatment
3. Availability of new medication(s) or indication(s)
4. Development of new technology
5. Advances in medical knowledge
6. Legislative, regulatory, or organizational changes effecting patient care

References:

Core Competencies: 1, 2, 3, 4, 5, 6, 7

Dr. Zakiya Rice is a board-certified dermatologist, pediatrician and pediatric dermatologist.

Dr. Rice received a Bachelor of Science degree in molecular biology from Princeton University in Princeton, NJ. She earned her medical degree from Washington School of Medicine in Seattle, WA. She completed her internship and pediatric residency at Seattle Children’s Hospital and Regional Medical Center in Seattle, WA, where she served as associate chief resident. Dr. Rice then completed a clinical research fellowship in the Department of Dermatology at Emory School of Medicine in Atlanta, GA, where she also completed her dermatology residency, serving as chief resident, and a pediatric dermatology fellowship.

Dr. Rice is an Assistant Professor of Dermatology and Pediatrics at Emory University.

She is a member of Alpha Omega Alpha National Medical Honor Society, American
Dr. Albert E. "Bo" Rivera, DO, FAOCD
A Play Yard of Dermatology Tips
This lecture will cover various accumulated tips relating to business, customer service, efficiency, medical dermatology, surgical dermatology and Mohs.

Objectives:
1. Discuss accumulated collection of business and customer service tips
2. Discuss accumulated collection of medical and surgical dermatology tips
3. Review and discuss the WAR (Webb and Rivera) Score

Needs:
1. New advances in dermatologic treatment
2. New methods of diagnosis or treatment
3. Availability of new medication(s) and indication(s)
4. Advances in medical knowledge
5. Legislative, regulatory, or organizational changes effecting patient care

References: Pending

Core Competencies: 1, 2, 3, 4, 5, 6

Dr. Albert E. "Bo" Rivera is a licensed physician and surgeon in Alabama, board-certified diplomat of the American Osteopathic College of Dermatology, a fellowship-trained member of the American College of Mohs Surgeons, as well as member of several dermatology and medical specialty organizations such as the American Society for Dermatologic Surgery, American Society for Mohs Surgery, American Academy of Dermatology, Skin Cancer Foundation and the Madison County Medical Society.

He was born and grew up in Haleyville, AL, graduating from Haleyville High School. Afterward, he completed his undergraduate education at Auburn University, earning a degree in premedicine and zoology. He completed his medical training at Kansas City University of Medicine and Biosciences in Kansas City, MO. His internship in general surgery was done at the University of Kentucky, in Lexington, KY, followed by an internal medicine residency at Northside Hospital and Heart Institute in Saint Petersburg, FL. At Northeast Regional Medical Center in Kirksville, MO, he completed both a dermatology residency as well as a dermatology research and laser fellowship under the direction of Lloyd J. Cleaver, DO. Upon completion of his residency, Dr. Rivera was nationally awarded the James Bernard, D.O. Residency Leadership Award based on integrity, respect, empowerment and initiative. The final honor in his training was completing a Mohs Micrographic Surgery subspecialty fellowship under the direction of Roger I. Ceilley, MD and Andrew K. Bean, MD in West Des Moines, IA. Over the years he has had the opportunity to publish several articles in national and international medical journals, as well as authoring chapters in medical textbooks and online. Dr. Rivera serves on the editorial board for the Journal of Clinical and Aesthetic Dermatology and the Journal of the American Osteopathic College of Dermatology, as well as serving on the AOCDO Editorial/Public Relations Committee and as an American Academy of Dermatology Liaison. He has also given presentations at local, national and international venues to both non-medical and medical professionals throughout his medical career.

Dr. Rivera enjoys multiple aspects within dermatology but has specific interest and extensive training in the prevention and treatment of skin cancers. Personally, he enjoys traveling, educating others, general fitness, as well as participating in and viewing multiple sports. Also, away from work, he enjoys time with his wife, Stephanie, a daughter who was born in 2015 and their Labradoodle.

Dr. Rivera has also been awarded the Doctor's Choice Award in Dermatology for Madison.

Advisory Board: Castle Biosciences

Peter Saitta, DO, FAOCD
Cutaneous Manifestations of Illegal Drug Use
This lecture will highlight the common and rare cutaneous manifestations of illegal drug use in the United States. It will also review the methods of drug use, the equipment utilized and the risk factors for these types of side effects.

Objectives:
1. Review common cutaneous physical exam signs and symptoms of illegal drug use
2. Review the common adulterants of drugs in the United States
3. Review the more exotic bacterial infections associated with drug use in the United States

Needs:
1. New advances in dermatologic treatment
2. Advances in medical knowledge
3. Legislative, regulatory, or organizational changes effecting patient care

References:
1. Bologna
2. Andrews
3. Duvvurier Atlas

Core Competencies: 1, 2, 3, 4, 5, 6, 7
Dr. Peter Saitta received his Bachelor of Arts from New York University and his medical degree from the University of Medicine and Dentistry of New Jersey. He completed his dermatology residency as chief resident at Oakwood Hospital. Dr. Saitta assists with the osteopathic dermatology residency program at St. John’s Hospital in New York and is also a clinical instructor of dermatology at NYU department of dermatology, where he assists in teaching the residents patch testing.

Disclosures: No disclosures provided by speaker

George Schmieder, DO, FAOCD

Local Flaps and Mohs Reconstruction and When to Use Them
This lecture will involve the planning and execution of a flap repair following Mohs surgery, which varies from case to case. This lecture will show the audience different approaches on how to close Mohs defects when simple closure is not indicated.

Objectives:
1. Help attendees understand that the methods of reconstruction are dependent on the depth/thickness of the defect and the overall shape and size of the wound
2. Help attendees understand which method is chosen must be an inherent upon vascular supply
3. Help attendees understand that reconstruction must consider maximal horizontal stabilization with minimal vertical tension

Needs:
1. New advances in dermatologic treatment
2. New methods of diagnosis and treatment
3. Advances in medical knowledge

References:

Core Competencies: 1, 2, 3, 4, 5, 6, 7

George J. Schmieder, DO, FAOCD, FAAD, is a board-certified dermatologist and Mohs Skin Cancer Surgeon. Dr. Schmieder completed his dermatology residency at the esteemed University of Miami. He is a subject level expert in cosmetic and laser dermatology, as well. His dedication to his community and country is evidenced by his 20+ year commitment to the U.S. Navy. Dr. Schmieder has earned a stellar reputation for performing Mohs surgery in Jacksonville. He is devoted to teaching and recently began the Park Avenue Dermatology Residency program. Academic research has also been one of his personal endeavors demonstrated by the many past and present clinical research studies to explore the latest techniques and use of new pharmaceuticals for the treatment of a variety of skin conditions and skin-related disorders, such as acne, atopic dermatitis, psoriasis, pre-cancerous skin lesions and more.

Disclosures: Owner of Park Avenue Dermatology, PA

Ben Stoff, MD

Contemporary Ethical Controversies in Dermatology
This lecture will define ethics, explain its importance to practicing dermatologists and apply ethical reasoning to contemporary controversies in dermatology.

Objectives:
1. Explain what an ethical dilemma is and how it can be analyzed
2. Describe conflict of interest and how it applies to in-office dermatopathology laboratories
3. Recount arguments in favor of and against free skin cancer screening events

Needs:
1. Legislative, regulatory, or organizational changes effecting patient care

References:

Core Competencies: 5

International Volunteerism in Dermatology: Short-Term Travel, Long-Term Impact
This lecture will define global health and emphasize the importance of dermatology in global health. It will also dispel common myths about short-term global health volunteer work. This lecture will also discuss the qualities of short-term projects that make them successful at carrying out the goals of global health. It will close by showing tropical diseases relevant to dermatology and model organizations.

Objectives:
1. Explain what global health is and why dermatologists should participate
2. Describe educational interventions that can be carried out successfully by the short-term volunteer.

3. List model organizations that facilitate short-term experiences in global health for dermatologists.

Needs:
1. Advances in medical knowledge

References:

Core Competencies: 2, 3, 4, 5

Benjamin Stoff, MD, holds a joint appointment as Assistant Professor in the Department of Dermatology and the Department of Pathology at Emory University School of Medicine. A board-certified dermatologist and dermatopathologist, Dr. Stoff specializes in the diagnosis and treatment of skin cancer and is a member of the multidisciplinary melanoma team at Winship Cancer Institute. He began practicing with Emory Healthcare in 2011.

Dr. Stoff is a fellow of the American Academy of Dermatology, the American Society of Dermatopathology and the Emory Center for Ethics. He is a member of American Academy of Dermatology, American Society of Dermatopathology, Emory University Hospital Ethics Committee, American Society of Bioethics and Humanities and Atlanta Society of Dermatology and Dermatologic Surgery.

Dr. Stoff attended medical school at the University of Texas Southwestern and completed his internship at Baylor University Medical Center. He then completed his residency in dermatology and fellowship in dermatopathology at Emory University School of Medicine. He is currently a student in the Masters in Bioethics Program at the Center for Ethics at Emory University.

Dr. Stoff’s research interests include bioethics, dermatopathology and melanoma. He is also interested in global health and has received the Skin Care in Developing Countries grant from the American Academy of Dermatology. He is a reviewer for the Journal of the American Academy of Dermatology and the Journal of Drugs in Dermatology.

Dr. Stoff has been elected Teacher of the Year in the dermatology department of Emory University School of Medicine for three consecutive years.

Disclosures: No disclosures provided by speaker

Lisa Swanson, MD

*Name That Nubbin!*

This lecture will provide an overview of various bumps and spots on the skin in children.

Objectives:
1. Review treatment options for pyogenic granulomas
2. Review congenital cysts on the neck
3. Review treatment options for warts and molluscum

Needs:
1. New advances in dermatologic treatment
2. New methods of diagnosis or treatment
3. Availability of new medication(s) or indication(s)
4. Advances in medical knowledge

References:

Core Competencies: 2, 3, 4, 5, 6

**Pediatric Dermatology Update**

This lecture will give an overview of new treatments from common pediatric dermatology issues.

Objectives:
1. Review new treatment options for pediatric dermatology issues
2. Review new details about common pediatric rashes
3. Review JAK inhibitors

Needs:
1. New advances in dermatologic treatment
2. New methods of diagnosis or treatment
3. Availability of new medication(s) or indication(s)
4. Development of new technology
5. Advances in medical knowledge

References:

Core Competencies: 2, 3, 4, 5, 6, 7

Dr. Swanson is a board-certified dermatologist. She was born in New Orleans, LA and raised in Scottsdale, AZ. She attended college at the University of Colorado at Boulder, graduating with honors as an English major. After that, she obtained her medical degree from Tulane University School of Medicine in New Orleans. She performed her internship at Mayo Clinic in Scottsdale, AZ and went on to complete her dermatology residency at Mayo Clinic in Rochester, MN. She completed a fellowship in pediatric dermatology at Phoenix Children's Hospital in Arizona.

Disclosures: Speaker for Valeant, Bayer; Advisory Board of Sanofi Regeneron, Amgen, Allergan

CORE/O’Bleness Memorial Hospital

Cutaneous Manifestations of Systemic Disease

Objectives:
1. Review key clinical characteristics of nutritional dermatoses
2. Formulate a differential diagnosis for a patient presenting with a nutritional dermatosis
3. Review appropriate workup and treatment for zinc deficiency and its differential

Needs:
1. New advances in dermatologic treatment
2. Advances in medical knowledge
3. New methods of diagnosis or treatment

References:

Core Competencies: 2, 3, 6, 7

Disclosures: No disclosures provided by speaker

KCU-GMEC/Dermatology Residency of Orlando

Papulosquamous, Lichenoid & Eczematous Dermatoses

Objectives:
1. Review new treatment options (including investigational drugs) for psoriasis and eczema
2. Review different types of PRP and unique characteristics of each
3. Review most commonly tested contact allergens

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge

References:

Core Competencies: 1, 2, 3, 4, 5, 6, 7

Disclosures: No disclosures provided by speaker

LECOMT/St. John's Episcopal Hospital

Figurate Erythemas and Purpuras

Objectives:
1. Review the diagnosis and treatment of erythemas
2. Review the diagnosis, pathogenesis and treatment of purpuras

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge

References:

Core Competencies: 2

Disclosures: Off-Label - We will be discussing investigational drugs for the treatment of psoriasis and eczema
Core Competencies: 2, 3

Disclosures: No disclosures provided by speakers

LECOMT/University Hospitals
Regional Hospitals
Acne & Related Disorders

Objectives:
1. Review the current guidelines of care for the management of acne vulgaris
2. Review the identification and management of acne-related dermatologic disorders
3. Review the application of osteopathic principles to acne vulgaris and related conditions

Needs:
1. Availability of new medication(s) or indication(s)
2. Advances in medical knowledge

References:

Core Competencies: 1, 2, 3

Disclosures: No disclosures provided by speakers

MWU/OPTI/Advanced Desert Dermatology
Neonatal Dermatology

Objectives:
1. Review high-yield highlights of neonatal dermatology for board review
2. Review clinically relevant pearls for managing common skin conditions in the neonatal period
3. Review literature to stay current with evidence-based practices in neonatal dermatology

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge

References:

Core Competencies: 2, 3, 6

Disclosures: Off-Label - Acitretin/isotretinoin for harlequin ichthyosis and collodion baby IVIG for sclerema neonatorum

MWU/OPTI/Affiliated Dermatology
Disorders of the Tongue and Nails

Objectives:
1. Review dermatologic mucosal membrane condition
2. Review dermatologic tongue disorders
3. Review dermatologic nail disorders

Needs:
1. Advances in medical knowledge
2. New methods of diagnosis or treatment

References:

Core Competencies: 2, 3, 6

Disclosures: No disclosures provided by speakers

NSUCOM/Broward Health Medical Center
Viral Dermatoses

Objectives:
1. Review various dermatologic correlations to the herpes viruses
2. Provide an awareness of possible dermatologic conditions that may result from various human papilloma viruses
3. Review various childhood exanthems and their potential implications

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge
4. New methods of diagnosis or treatment
5. Development of new technology

References:

Core Competencies: 2

Disclosures: No disclosures provided by speakers
JUBLIA allows some patients to have clearer toenails grow back. Individual results may vary.

INDICATION
JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

IMPORTANT SAFETY INFORMATION
- JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
- Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
- The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
- JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.

Please see Brief Summary of full Prescribing Information on the adjacent page.
Reference: 1. JUBLIA [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC.
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This Brief Summary does not include all the information needed to use JUBLIA safely and effectively. See full prescribing information for JUBLIA.

JUBLIA® (efinaconazole) topical solution, 10%
For topical use
Initial U.S. Approval: 2014

INDICATIONS AND USAGE
JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

DOSAGE AND ADMINISTRATION
Apply JUBLIA to affected toenails once daily for 48 weeks, using the integrated flow-through brush applicator. When applying JUBLIA, ensure the toenail, the toenail fold, toenail bed, hyponychium, and the undersurface of the toenail plate, are completely covered.

JUBLIA is for topical use only and not for oral, ophthalmic, or intravaginal use.

CONTRAINDICATIONS
None.

ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two clinical trials, 1227 subjects were treated with JUBLIA, 1161 for at least 24 weeks and 760 for 48 weeks. Adverse reactions reported within 48 weeks of treatment and in at least 1% of subjects treated with JUBLIA and those reported in subjects treated with the vehicle are presented in Table 1.

Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks

<table>
<thead>
<tr>
<th>Adverse Event, n (%)</th>
<th>JUBLIA N = 1227</th>
<th>Vehicle N = 413</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingrown toenail</td>
<td>28 (2.3%)</td>
<td>3 (0.7%)</td>
</tr>
<tr>
<td>Application site dermatitis</td>
<td>27 (2.2%)</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Application site vesicles</td>
<td>20 (1.6%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Application site pain</td>
<td>13 (1.1%)</td>
<td>1 (0.2%)</td>
</tr>
</tbody>
</table>

DRUG INTERACTIONS
In vitro studies have shown that JUBLIA, at therapeutic concentrations, neither inhibits nor induces cytochrome P450 (CYP450) enzymes.

USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies with JUBLIA in pregnant women. JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Systemic embryofetal development studies were conducted in rats and rabbits. Subcutaneous doses of 2, 10 and 50 mg/kg/day efinaconazole were administered during the period of organogenesis (gestational days 6-16) to pregnant female rats. In the presence of maternal toxicity, embryofetal toxicity (increased embryofetal deaths, decreased number of live fetuses, and placental effects) was noted at 50 mg/kg/day [559 times the Maximum Recommended Human Dose (MRHD) based on Area Under the Curve (AUC) comparisons]. No embryofetal toxicity was noted at 10 mg/kg/day (112 times the MRHD based on AUC comparisons). No malformations were observed at 50 mg/kg/day (559 times the MRHD based on AUC comparisons).

Subcutaneous doses of 1, 5, and 10 mg/kg/day efinaconazole were administered during the period of organogenesis (gestational days 6-19) to pregnant female rabbits. In the presence of maternal toxicity, there was no embryofetal toxicity or malformations at 10 mg/kg/day (154 times the MRHD based on AUC comparisons).

In a pre- and post-natal development study in rats, subcutaneous doses of 1, 5, and 25 mg/kg/day efinaconazole were administered from the beginning of organogenesis (gestational day 6) throughout the end of lactation (lactation day 29). In the presence of maternal toxicity, embryofetal toxicity (increased prenatal pup mortality, reduced live litter sizes and increased postnatal pup mortality) was noted at 25 mg/kg/day. No embryofetal toxicity was noted at 5 mg/kg/day (17 times the MRHD based on AUC comparisons). No effects on postnatal development were noted at 25 mg/kg/day (89 times the MRHD based on AUC comparisons).

Nursing Mothers
It is not known whether efinaconazole is excreted in human milk. After repeated subcutaneous administration, efinaconazole was detected in milk of nursing rats. Because many drugs are excreted in human milk, caution should be exercised when JUBLIA is administered to nursing women.

Pediatric Use
Safety and effectiveness of JUBLIA in pediatric subjects have not been established.

Geriatric Use
Of the total number of subjects in clinical trials of JUBLIA, 11.3% were 65 and over, while none were 75 and over. No overall differences in safety and effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and the younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
A 2-year dermal carcinogenicity study in mice was conducted with daily topical administration of 3%, 10% and 30% efinaconazole solution. Severe irritation was noted at the treatment site in all dose groups, which was attributed to the vehicle and confounded the interpretation of skin effects by efinaconazole. The high dose group was terminated at week 34 due to severe skin reactions. No drug-related neoplasms were noted at doses up to 10% efinaconazole solution (248 times the MRHD based on AUC comparisons).

Efinaconazole revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and Chinese hamster lung cell chromosome aberration assay) and one in vivo genotoxicity test (mouse peripheral reticulocyte micronucleus assay).

No effects on fertility were observed in male and female rats that were administered subcutaneous doses up to 25 mg/kg/day efinaconazole (279 times the MRHD based on AUC comparisons) prior to and during early pregnancy. Efinaconazole delayed the estrous cycle in females at 25 mg/kg/day but not at 5 mg/kg/day (56 times the MRHD based on AUC comparisons).

PATIENT COUNSELING INFORMATION
See FDA-Approved Patient Labeling (Patient Information).

VALEANT
Pharmaceuticals North America LLC
Manufactured for: Valenta Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA
Manufactured by: Valenta Pharmaceuticals International, Inc., Laval, Quebec H7L 4A8, Canada

JUBLIA is a trademark of Valenta Pharmaceuticals International, Inc. or its affiliates.
© Valenta Pharmaceuticals North America LLC
U.S. Patents 8,039,494; 7,214,506
Based on 9462903
JUBL.0130.USA.16 Issued: 09/2016

Core Competencies: 2, 3, 4, 6, 7

Disclosures: No disclosures provided by speakers

NYCOMEC/Palisades Medical Center

Cysts and Disorders of the Hair

Objectives:
1. Review the diagnosis of common disorders affecting the hair and scalp with treatment options
2. Review the technique for performing a scalp biopsy
3. Identify and describe the clinical and histopathologic features of cysts

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge
4. New methods of diagnosis or treatment

References:

Core Competencies: 2, 3, 6

Disclosures: No disclosures provided by speakers

References:

Core Competencies: 1, 2, 3, 4, 5, 6, 7

Disclosures: No disclosures provided by speakers

OMNEE/LewisGale Hospital-Montgomery

Granulomatous, Metabolic and Depositional Diseases

Objectives:
1. Review the clinical presentation of granulomatous, metabolic and depositional diseases
2. Review the treatment options for granulomatous, metabolic and depositional diseases
3. Review high-yield board-relevant information pertinent to granulomatous, metabolic and depositional diseases

Needs:
1. New advances in dermatologic treatment
2. Advances in medical knowledge
3. New methods of diagnosis or treatment

References:

Core Competencies: 1, 2, 3, 4, 5, 6, 7

Disclosures: No disclosures provided by speakers

References:

Core Competencies: 2, 3

Disclosures: No disclosures provided by speaker

OPTI-West/Silver Falls Dermatology

Pediatric Dermatology: Pigmented Lesions

Objectives:
1. Identify common pediatric dermatoses
2. Identify the most common features of pediatric pigmented lesions
3. Differentiate between spitz nevus and melanoma

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge

References:

Core Competencies: 2, 3, 6, 7

Disclosures: No disclosures provided by speakers

PCOM/Lehigh Valley Health Network
Premalignant and Malignant Non-Melanoma Skin Cancer

Objectives:
1. Review basic knowledge regarding premalignant and malignant dermatologic lesions
2. Discuss up-to-date literature on staging and managing high risk squamous cell carcinoma
3. Evaluate new treatment modalities for premalignant and malignant lesions

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge
4. New methods of diagnosis or treatment

References:

Core Competencies: 1, 2

Disclosures: No disclosures provided by speaker

RMOPTI/Colorado Dermatology Institute
Genodermatoses

Objectives:
1. Review high-yield clinical findings for common genodermatoses
2. Review treatment options and appropriate referrals for genodermatoses patients
3. Match specific eye/ear findings unique to individual genodermatoses

Needs:
1. New advances in dermatologic treatment
2. Advances in medical knowledge

References:

Core Competencies: 1, 2, 3, 4, 5, 6

Disclosures: No disclosures provided by speakers

SCS/MSUCOM/Oakwood Healthcare System
Pediatric Blistering Diseases

Objectives:
1. Review the pathophysiology and presentation of pediatric bullous disorders
2. Review board-relevant dermatopathology associated with pediatric bullous disorders
3. Review advancements of treatment options for pediatric bullous disorders, including gene therapy

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge
4. Development of new technology

References:

Core Competencies: 2, 3, 6

Disclosures: No disclosures provided by speakers

Still OPTI/Northeast Regional Medical Center
Infectious Diseases: Fungal

Objectives:
1. Review the characteristics of superficial fungal infections
2. Review the characteristics of deep fungal infections
3. Review the treatment of fungal infections

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge
4. New methods of diagnosis or treatment

References:

Core Competencies: 2

Disclosures: No disclosures provided by speakers

Texas OPTI/South Texas Osteopathic Dermatology
Photo and Pregnancy Related Dermatoses

Objectives:
1. Review the differences between major pregnancy related dermatoses
2. Review photoprotection as it pertains to the treatment of photodermatoses
3. Review when to appropriately engage other specialists, including OB/GYN, during the evaluation and management of pregnancy dermatoses

Needs:
1. New advances in dermatologic treatment
2. Availability of new medication(s) or indication(s)
3. Advances in medical knowledge
4. New methods of diagnosis or treatment

References:

Core Competencies: 2, 3, 7

Disclosures: No disclosures provided by speaker

Texas OPTI/UNTHSC Eosinophilic and Neutrophilic Dermatoses

Objectives:
1. Review basic neutrophil and eosinophil biology and how these cells contribute to the pathophysiology of the disorders discussed
2. Review how to diagnose, evaluate and treat neutrophilic dermatoses and various dermatologically-significant neutrophilic disorders
3. Review how to diagnose, evaluate and treat eosinophilic dermatoses and various dermatologically-significant eosinophilic disorders

Needs:
1. Advances in medical knowledge
2. New methods of diagnosis or treatment

References:

Core Competencies: 2, 3, 4, 6

Disclosures: No disclosures provided by speakers

HELP WANTED

An exceptional Dermatology opportunity in the east valley of Phoenix awaits. This position is minutes away from Phoenix-Mesa Gateway and close to Sky Harbor International airports. Many outdoor activities including golf, camping, hiking, biking, are near. World class shopping, dining, and both college and professional sports teams are available. Outstanding educational opportunities are in the area with both public and private schools. Sunshine is year round!

THE PRACTICE:
New Dermatology practice with amazing growth potential
Medical, surgical, and cosmetic dermatology available
Mohs surgery in house
Hassle free EMR with MAs trained as scribes
1-year base salary plus bonus and incentives
Sign-on bonus/moving expenses available

For more details send contact information to:
hwdermatology@gmail.com
Join Us For Upcoming AOCD Events

2017 Fall Meeting
Intercontinental | New Orleans | October 25-28

2018 Spring Meeting
Hilton | West Palm Beach | March 21-24

2018 Fall Meeting
Westin | San Diego | October 9-13